Investigating how viruses that infect bacteria affect respiratory diseases
Studies on bacteriophages in respiratory diseases
This study is looking at special viruses called bacteriophages that can attack harmful bacteria in the lungs, aiming to find new ways to help people with chronic respiratory infections, especially those caused by tough bacteria that don't respond to regular antibiotics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10871710 on NIH RePORTER |
What this research studies
This research focuses on bacteriophages, which are viruses that specifically target bacteria, and their role in respiratory diseases, particularly in patients with chronic infections. The project aims to understand how these phages interact with bacterial pathogens like Pseudomonas aeruginosa, which is known to cause severe airway infections. By exploring the mechanisms of phage action and their potential to influence antibiotic resistance, the research seeks to develop new therapeutic strategies. Patients may benefit from insights gained into how to better manage or treat bacterial infections that are resistant to current antibiotics.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients suffering from chronic respiratory infections, particularly those with cystic fibrosis or other conditions that predispose them to bacterial infections.
Not a fit: Patients with non-bacterial respiratory conditions or those who do not have chronic infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for respiratory diseases caused by antibiotic-resistant bacteria.
How similar studies have performed: Previous research has shown promise in using bacteriophages to combat bacterial infections, indicating that this approach could be a viable treatment option.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Bollyky, Paul L — Stanford University
- Study coordinator: Bollyky, Paul L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.